It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Heme serves as a prosthetic group in hemoproteins, including subunits of the mammalian mitochondrial electron transfer chain. The first enzyme in vertebrate heme biosynthesis, 5-aminolevulinic acid synthase 1 (ALAS1), is ubiquitously expressed and essential for producing 5-aminolevulinic acid (ALA). We previously showed that Alas1 heterozygous mice at 20–35 weeks (aged-A1+/−s) manifested impaired glucose metabolism, mitochondrial malformation in skeletal muscle, and reduced exercise tolerance, potentially linked to autophagy dysfunction. In this study, we investigated autophagy in A1+/−s and a sarcopenic phenotype in A1+/−s at 75–95 weeks (senile-A1+/−s). Senile-A1+/−s exhibited significantly reduced body and gastrocnemius muscle weight, and muscle strength, indicating an accelerated sarcopenic phenotype. Decreases in total LC3 and LC3-II protein and Map1lc3a mRNA levels were observed in aged-A1+/−s under fasting conditions and in Alas1 knockdown myocyte-differentiated C2C12 cells (A1KD-C2C12s) cultured in high- or low-glucose medium. ALA treatment largely reversed these declines. Reduced AMP-activated protein kinase (AMPK) signaling was associated with decreased autophagy in aged-A1+/−s and A1KD-C2C12s. AMPK modulation using AICAR (activator) and dorsomorphin (inhibitor) affected LC3 protein levels in an AMPK-dependent manner. Our findings suggest that heme deficiency contributes to accelerated sarcopenia-like defects and reduced autophagy in skeletal muscle, primarily due to decreased AMPK signaling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Yamagata University Faculty of Medicine, Department of Functional Genomics, Major of Innovative Medical Science Research, Yamagata University School of Medicine/Research Center for Molecular Genetics, Institute for Promotion of Medical Science Research, Yamagata, Japan (GRID:grid.268394.2) (ISNI:0000 0001 0674 7277); Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery, Yamagata, Japan (GRID:grid.268394.2) (ISNI:0000 0001 0674 7277)
2 Yamagata University Faculty of Medicine, Department of Functional Genomics, Major of Innovative Medical Science Research, Yamagata University School of Medicine/Research Center for Molecular Genetics, Institute for Promotion of Medical Science Research, Yamagata, Japan (GRID:grid.268394.2) (ISNI:0000 0001 0674 7277)
3 KIYAN PHARMA Co., Ltd., Tokyo, Japan (GRID:grid.268394.2)
4 SBI Pharmaceuticals Co., Ltd., Tokyo, Japan (GRID:grid.476775.0)
5 KIYAN PHARMA Co., Ltd., Tokyo, Japan (GRID:grid.476775.0)
6 Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery, Yamagata, Japan (GRID:grid.268394.2) (ISNI:0000 0001 0674 7277)